Registration Info

This is a 1-day meeting and will provide 6 CE/CME credits.

Conference Registration Fee

Practicing Healthcare Professionals: $129

Non-Clinicians / Medical Office Support Staff / Industry Participants

In order to maintain the clinical nature of the conference, nonclinicians—including, but not limited to, office managers, billing specialists, receptionists, and administrative staff; guests, spouses, friends, and/or family members—may not attend PAINWeekEnd.


Unfortunately, we do not have discounts available on hotel rooms. Please contact the hotel directly should you require accommodations.

Hyatt Centric French Quarter New Orleans
800 Iberville St.
New Orleans, LA 70112

View hotel website >>


Get Directions using Google Maps


Faculty and courses are subject to change. Please refer to the online schedule below for the most recent course descriptions.

To view the schedule below, click on the + sign next to the day of the conference to expand the conference agenda. Click on the + signs within the agenda to view the course description, UAN number, and AANP pharmacology credits.

*not certified for credit

Saturday, June 8, 2019


    Coffee will be served.

  • Rational Polypharmacy: An Update for Specific Conditions

    Rational polypharmacy or the use of multiple medications to manage the same disease state or condition has been a part of treatment approaches for chronic pain for many years. This course will review the concept of rational polypharmacy as it applies to the treatment of migraine, neuropathic pain, and musculoskeletal pain conditions.

    • UAN: 0530-0000-19-032-L01-P
    • AANP Rx Hours: 0.00

    Breakfast will be served.

    Sponsored by Legally Mine.


  • What’s All the “GABA” About? Pregabalin and Gabapentin Abuse

    The gabapentinoids are a popular class of medications among prescribers for use in chronic pain and various other neurological conditions. In fact, prescription rates for both gabapentin and pregabalin have increased in the United States and other countries in recent years. However, these medications have a street value to a newer niche of users, including patients taking them at megadoses to enhance the effects of other psychotropic drugs, and other patients taking them to manage or mitigate opioid withdrawal symptoms and possibly even opioid cravings. While pregabalin is already classified as a controlled substance, gabapentin does not yet carry this classification. In response to rising abuse, various states and regulatory bodies are considering changes to enhance patient safety and protect the provider’s license. Learn what changes you should make to your practice, if any, in light of the growing abuse of gabapentinoids and how to identify patients potentially abusing them.

    • UAN: 0530-0000-19-044-L01-P
    • AANP Rx Hours: 0.00
  • Unveiling the Mask: The Relationship of Chronic Pain and Psychopathology

    When tapering opioid therapy, frontline practitioners may at times be faced with chronic pain patients suffering from undiagnosed mental health disorders. In most cultures, the majority of mental health cases go unrecognized in primary care settings. About 60% of previously undetected cases could have been recognized if the patients had been evaluated for a mental health disorder. Research has shown that chronic pain is most often associated with depression, anxiety, and somatoform, personality, and substance use disorders, but less is known about the relationship with other conditions, such as schizophrenia spectrum/psychotic, sleep-wake, bipolar, neurocognitive, obsessive compulsive, and dissociative disorders. The purpose of this presentation is to help providers learn more about mental health disorders, how they are defined, and how the definitions have changed in the latest Diagnostic and Statistical Manual of Mental Disorders. The results of a pilot study looking at the prevalence rates of these new DSM disorders among patients who suffer from chronic pain will be delineated.

    • UAN: 0530-0000-19-042-L01-P
    • AANP Rx Hours: 0.10



    Lunch will be served.

    Sponsored by SCILEX.

  • Migraine Headache: New and Emerging Therapies

    This presentation will offer attendees insight into the burden experienced by people suffering from migraine headaches. We will examine new advances in both our understanding of migraines and the pathophysiology of migraines that may lead to new treatments.

    • UAN: 0530-0000-19-056-L01-P
    • AANP Rx Hours: 0.20

  • 3's Company: COX-2 Inhibitors, Medicinal Marijuana, and Opioid Prescribing

    There is much controversy around many aspects of pain treatment, and compelling arguments have focused on both sides of the fence regarding appropriate opioid use and prescribing, legalization of marijuana, and the safety of cox-2 inhibitors. In all  3 cases, there are issues associated with strong positions, although the evidence, when put into practice, is less black and white. For each topic, we will evaluate current literature and debate the clinical, legal, and ethical controversies surrounding recent developments in pain management. Attendees will get a better understanding as presenters debate evidence based application of the cdc guidelines in various clinical settings, evaluate clinical and ethical concerns regarding marijuana for medicinal or recreational use, and take a critical look at the literature and its application when using cox-2 inhibitors for treating pain.

    • UAN: 0530-0000-19-050-L01-P
    • AANP Rx Hours: 0.00
  • The Gentle Art of Saying No: How to Establish Appropriate Boundaries With Chronic Pain Patients

    Effective pain management has been deemed a human right, but some chronic pain patients perceive that to mean they are entitled to opioid analgesics for prolonged pain control. In response to these expectations, providers may feel pressured to say “Yes” and continue prescribing opioids, thereby reinforcing the patient’s beliefs and reliance on medication. This has contributed to a dramatic rise in opioid analgesic misuse and deaths from prescription drug overdose. In fact, the CDC has identified opioid misuse as a “public health epidemic” and released new guidelines in March 2016. While a collaborative relationship is optimal for pain management, there may be times when a practitioner saying “No” is the best treatment. Many providers feel uncomfortable setting boundaries; however, boundary setting is important work because rights as a provider are also important. When reasonable limits are placed on a patient and the patient continues to step beyond those limits, it is imperative that providers maintain boundaries and be consistent in their message. Participants will learn about the gentle art of saying “No” and how to use a decision tree when making pain management decisions. Sample cases will be presented along with recommended treatment strategies.

    • UAN: 0530-0000-19-058-L01-P
    • AANP Rx Hours: 0.00


To accompany and enrich your experience at the PAINWeekEnd conference, be sure to attend one or more of the sponsored programs, which are scheduled during breakfast, lunch, and afternoon "Brain Food" time slots in the schedule. There is NO ADDITIONAL CHARGE to attend these program sessions!